NAMACIZUMAB



NAME OF DRUG : NAMACIZUMAB

ALSO KNOWN AS : RYI-018 or JNJ-2463

LABORATORY : BIRDROCKBIO

STATUS AND ADVANCEMENT

Type of drug : NAMA-CB1

Clinical trials advancement : Analysing Results Phase 1

Estimated time to market : 127 months.

LABORATORY ABSTRACT ON THE DRUG

Discovered internally through Bird Rock Bio’s proprietary iCAPS platform, namacizumab is scheduled to be the first and only known NAMA to the CB1 receptor to be entering clinical trials. Namacizumab is a multi-modal therapeutic candidate with fibrotic, inflammatory and metabolic mechanisms of action.  This provides for the opportunity for namacizumab to have significant potential across a broad range of fibrotic and metabolic diseases including large unmet medical conditions such as NASH and diabetic nephropathy.

RECENT NEWS ON NAMACIZUMAB

SOME PUBLICATIONS RELATED WITH NAMACIZUMAB

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH NAMACIZUMAB


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE